Summary:
- The article reports on the FDA's approval of the first mRNA-based influenza vaccine, marking a significant technological shift in how seasonal flu immunizations are developed and manufactured.
- It highlights potential safety concerns and clinical trial data associated with this new class of vaccine, emphasizing the necessity for ongoing post-market surveillance and scientific scrutiny of mRNA platform efficacy in non-COVID applications.